BR0113286A - Pirazóis substituìdos - Google Patents
Pirazóis substituìdosInfo
- Publication number
- BR0113286A BR0113286A BR0113286-5A BR0113286A BR0113286A BR 0113286 A BR0113286 A BR 0113286A BR 0113286 A BR0113286 A BR 0113286A BR 0113286 A BR0113286 A BR 0113286A
- Authority
- BR
- Brazil
- Prior art keywords
- substituted pyrazoles
- pirazoes
- cathepsin
- treat
- pyrazoles
- Prior art date
Links
- 150000003217 pyrazoles Chemical class 0.000 title abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 108090000613 Cathepsin S Proteins 0.000 abstract 1
- 102100035654 Cathepsin S Human genes 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22517800P | 2000-08-14 | 2000-08-14 | |
US09/927,324 US6953793B2 (en) | 2000-08-14 | 2001-08-10 | Substituted pyrazoles |
PCT/US2001/025290 WO2002014315A2 (en) | 2000-08-14 | 2001-08-10 | Substituted pyrazoles |
Publications (3)
Publication Number | Publication Date |
---|---|
BR0113286A true BR0113286A (pt) | 2003-09-09 |
BR0113286B1 BR0113286B1 (pt) | 2013-04-16 |
BRPI0113286B8 BRPI0113286B8 (pt) | 2021-05-25 |
Family
ID=26919364
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0113286A BRPI0113286B8 (pt) | 2000-08-14 | 2001-08-10 | pirazóis substituídos e composição farmacêutica compreendendo os mesmos. |
Country Status (20)
Country | Link |
---|---|
US (2) | US6953793B2 (pt) |
EP (1) | EP1309593B1 (pt) |
JP (1) | JP5049447B2 (pt) |
KR (1) | KR100837193B1 (pt) |
AT (1) | ATE320427T1 (pt) |
AU (2) | AU2001286454B2 (pt) |
BR (1) | BRPI0113286B8 (pt) |
CA (1) | CA2419552C (pt) |
CZ (1) | CZ307185B6 (pt) |
DE (1) | DE60118004T2 (pt) |
DK (1) | DK1309593T3 (pt) |
ES (1) | ES2261463T3 (pt) |
HK (1) | HK1055422A1 (pt) |
HU (1) | HU230538B1 (pt) |
MX (1) | MXPA03001422A (pt) |
NZ (1) | NZ524191A (pt) |
PL (1) | PL213103B1 (pt) |
PT (1) | PT1309593E (pt) |
RU (1) | RU2317988C2 (pt) |
WO (1) | WO2002014315A2 (pt) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6566372B1 (en) * | 1999-08-27 | 2003-05-20 | Ligand Pharmaceuticals Incorporated | Bicyclic androgen and progesterone receptor modulator compounds and methods |
US20050101587A9 (en) * | 2000-08-14 | 2005-05-12 | Butler Christopher R. | Method for treating allergies using substituted pyrazoles |
BRPI0113286B8 (pt) * | 2000-08-14 | 2021-05-25 | Johnson & Johnson | pirazóis substituídos e composição farmacêutica compreendendo os mesmos. |
ES2281434T3 (es) * | 2000-08-14 | 2007-10-01 | Ortho-Mcneil Pharmaceutical, Inc. | Pirazoles sustituidos. |
JP2004523506A (ja) * | 2000-12-22 | 2004-08-05 | アクシス・ファーマシューティカルズ・インコーポレイテッド | カテプシン阻害剤としての新規な化合物と組成物 |
HUP0401109A3 (en) * | 2001-04-18 | 2007-12-28 | Euro Celtique Sa | Nociceptin analogs, their use and pharmaceutical compositions containing them |
KR100729242B1 (ko) * | 2001-04-18 | 2007-06-15 | 유로-셀티크 소시에떼 아노뉨 | 노시셉틴 유사체 |
US20040147503A1 (en) * | 2002-06-04 | 2004-07-29 | Sheila Zipfeil | Novel compounds and compositions as cathepsin inhibitors |
MXPA05003254A (es) | 2002-09-24 | 2005-06-08 | Novartis Ag | Agonistas del receptor de esfingosina-1-fosfato en el tratamiento de trastornos de desmielinacion. |
US7384970B2 (en) | 2003-03-24 | 2008-06-10 | Irm Llc | Inhibitors of cathepsin S |
US7109243B2 (en) | 2003-03-24 | 2006-09-19 | Irm Llc | Inhibitors of cathepsin S |
US7173051B2 (en) | 2003-06-13 | 2007-02-06 | Irm, Llc | Inhibitors of cathepsin S |
US7256207B2 (en) | 2003-08-20 | 2007-08-14 | Irm Llc | Inhibitors of cathepsin S |
FR2885904B1 (fr) * | 2005-05-19 | 2007-07-06 | Aventis Pharma Sa | Nouveaux derives du fluorene, compositions les contenant et utilisation |
SG10201504801VA (en) * | 2005-06-22 | 2015-07-30 | Chemocentryx Inc | Azaindazole compounds and methods of use |
TW200813018A (en) | 2006-06-09 | 2008-03-16 | Astrazeneca Ab | Novel compounds |
CL2007003590A1 (es) * | 2006-12-12 | 2008-02-29 | Wyeth Corp | Compuestos derivados de aril sulfamida; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en prevencion y tratamiento de sintomas vasomotrices, disfuncion sexual, transtornos gastrointestinales, transt |
US20080207683A1 (en) * | 2007-02-15 | 2008-08-28 | Darin Allen | Biaryl-substituted tetrahydro-pyrazolo-pyridine modulators of cathepsin s |
US20080269241A1 (en) * | 2007-02-15 | 2008-10-30 | Darin Allen | Bicyclic aminopropyl tetrahydro-pyrazolo-pyridine modulators of cathepsin s |
US20090118274A1 (en) * | 2007-02-15 | 2009-05-07 | Darin Allen | Monocyclic aminopropyl tetrahydro-pyrazolo-pyridine modulators of cathepsin s |
US20080200454A1 (en) * | 2007-02-15 | 2008-08-21 | Ameriks Michael K | Carbon-linked tetrahydro-pyrazolo-pyridine modulators of cathepsin s |
US20090099157A1 (en) * | 2007-02-15 | 2009-04-16 | Ameriks Michael K | Tetrahydro-pyrazolo-pyridine thioether modulators of cathepsin s |
US8119661B2 (en) | 2007-09-11 | 2012-02-21 | Astrazeneca Ab | Piperidine derivatives and their use as muscarinic receptor modulators |
EP3011958A1 (en) | 2008-06-20 | 2016-04-27 | Novartis AG | Paediatric compositions for treating multiple sclerosis |
US9643922B2 (en) | 2008-08-18 | 2017-05-09 | Yale University | MIF modulators |
US9540322B2 (en) | 2008-08-18 | 2017-01-10 | Yale University | MIF modulators |
US20120040974A1 (en) * | 2008-08-18 | 2012-02-16 | Yale University | Mif modulators |
TWI475020B (zh) * | 2009-03-12 | 2015-03-01 | The substituted nicotine amide as a KCNQ2 / 3 modifier | |
BR112012003270A2 (pt) | 2009-08-12 | 2019-09-24 | Janssen Pharmaceutica Nv | processo para a preparação de inibidores de catepsina s |
WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
PT3176170T (pt) | 2012-06-13 | 2019-02-05 | Incyte Holdings Corp | Compostos tricíclicos substituídos como inibidores de fgfr |
US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
CA2890018A1 (en) | 2012-11-05 | 2014-05-08 | Nant Holdings Ip, Llc | Substituted indol-5-ol derivatives and their therapeutical applications |
ES2625945T3 (es) | 2012-11-14 | 2017-07-21 | Glaxosmithkline Llc | Tieno[3,2-c]piridin-4(5H)-onas como inhibidores de bet |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
RU2015143657A (ru) | 2013-03-15 | 2017-04-27 | Нэнтбайосайенс, Инк. | Замещенные производные индол-5-ола и их терапевтические применения |
PE20152033A1 (es) | 2013-04-19 | 2016-01-21 | Incyte Holdings Corp | Heterociclos bicicliclos como inhibidores de fgfr |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
EP3227282B1 (en) * | 2014-12-02 | 2019-04-03 | F.Hoffmann-La Roche Ag | Novel piperidine derivatives |
EP3617205B1 (en) | 2015-02-20 | 2021-08-04 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
LT3319959T (lt) | 2015-07-06 | 2021-12-27 | Alkermes, Inc. | Histono deacetilazės hetero-halogeno inhibitoriai |
WO2017007755A1 (en) | 2015-07-06 | 2017-01-12 | Rodin Therapeutics, Inc. | Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase |
SG11201906164RA (en) | 2017-01-11 | 2019-08-27 | Rodin Therapeutics Inc | Bicyclic inhibitors of histone deacetylase |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
JP7152471B2 (ja) | 2017-08-07 | 2022-10-12 | ロダン・セラピューティクス,インコーポレーテッド | ヒストン脱アセチル化酵素の二環阻害剤 |
EP3694322A1 (en) | 2017-10-09 | 2020-08-19 | Terumo BCT Biotechnologies, LLC | Lyophilization container and method of using same |
CN112867716A (zh) | 2018-05-04 | 2021-05-28 | 因赛特公司 | Fgfr抑制剂的固体形式和其制备方法 |
CA3099116A1 (en) | 2018-05-04 | 2019-11-07 | Incyte Corporation | Salts of an fgfr inhibitor |
WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
CA3224729A1 (en) | 2019-03-14 | 2020-09-17 | Terumo Bct Biotechnologies, Llc | Lyophilization loading tray assembly and system |
WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
JOP20220083A1 (ar) | 2019-10-14 | 2023-01-30 | Incyte Corp | حلقات غير متجانسة ثنائية الحلقة كمثبطات لـ fgfr |
US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
CA3162010A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Derivatives of an fgfr inhibitor |
CA3163875A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
US11939331B2 (en) | 2021-06-09 | 2024-03-26 | Incyte Corporation | Tricyclic heterocycles as FGFR inhibitors |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US856514A (en) * | 1907-03-15 | 1907-06-11 | William T Adams | Cheese-cutter. |
US3743409A (en) | 1971-06-11 | 1973-07-03 | Xerox Corp | Cutter assembly |
JPS5090172A (pt) | 1973-12-13 | 1975-07-19 | ||
US3994890A (en) | 1974-01-31 | 1976-11-30 | Chugai Seiyaku Kabushiki Kaisha | 1-Aminoalkyl, 3-phenyl indazoles |
JPS5640714B2 (pt) * | 1974-03-04 | 1981-09-22 | ||
DK27383A (da) | 1982-02-17 | 1983-08-18 | Lepetit Spa | Fremgangsmaade til fremstilling af pyrazol(4,3-c)pyridiner |
JPH0615542B2 (ja) * | 1986-07-22 | 1994-03-02 | 吉富製薬株式会社 | ピラゾロピリジン化合物 |
FR2642759B1 (fr) | 1989-02-09 | 1991-05-17 | Laboratorios Esteve Sa | Derives de pyrimidyl-piperazinyl-alkyl azoles avec activite anxiolytique et/ou tranquillisante |
FR2673628B1 (fr) | 1991-03-07 | 1993-07-09 | Esteve Labor Dr | Procede de preparation de derives d'aryl (ou heteroaryl)-piperazinyl-butyl-azoles. |
US5264576A (en) | 1992-10-22 | 1993-11-23 | Hoechst-Roussel Pharmaceuticals Incorporated | Pyrazolo[4,3-c]pyridines which are intermediates |
FR2705962B1 (fr) * | 1993-06-03 | 1995-07-13 | Rhone Poulenc Agrochimie | Arylpyrazoles fongicides. |
FR2712808B1 (fr) | 1993-11-25 | 1996-02-16 | Esteve Labor Dr | Utilisation des dérivés de 1-{4-[4-aryl(ou hétéroaryl)-1-pipérazinyl]-butyl}-1-H-azole pour la préparation de médicaments destinés au traitement des troubles de la sécrétion gastrique . |
IL112759A0 (en) | 1994-02-25 | 1995-05-26 | Khepri Pharmaceuticals Inc | Novel cysteine protease inhibitors |
US5776718A (en) | 1995-03-24 | 1998-07-07 | Arris Pharmaceutical Corporation | Reversible protease inhibitors |
JPH11503417A (ja) | 1995-03-24 | 1999-03-26 | アリス・ファーマシューティカル・コーポレイション | 可逆的プロテアーゼインヒビター |
TW438591B (en) | 1995-06-07 | 2001-06-07 | Arris Pharm Corp | Reversible cysteine protease inhibitors |
FR2742052B1 (fr) | 1995-12-12 | 1998-04-10 | Esteve Labor Dr | Utilisation des derives 1-(4-(4-aryl (ou heteroaryl)-1-piper azinyl)-buty)-1h-azole pour le traitement de la depression, des troubles obsessifs compulsifs, l'apnee du sommeil, les dysfonctions sexuelles, l'emese et le mal des transports |
JP2000509376A (ja) | 1996-04-22 | 2000-07-25 | マサチューセッツ インスティテュート オブ テクノロジー | カテプシンsの阻害を通しての免疫応答の抑制 |
AU7553198A (en) * | 1997-06-12 | 1998-12-30 | Sumitomo Pharmaceuticals Company, Limited | Pyrazole derivatives |
ID24931A (id) | 1997-11-05 | 2000-08-31 | Novartis Ag | Dipeptida nitril |
GB9806287D0 (en) | 1998-03-24 | 1998-05-20 | Synphar Lab Inc | Monobactam enzyme inhibitors |
WO1999058153A1 (en) | 1998-05-08 | 1999-11-18 | Brigham & Women's Hospital | Methods of diagnosing and modulating autoimmunity |
JP2002537294A (ja) | 1999-02-20 | 2002-11-05 | アストラゼネカ アクチボラグ | カテプシンl及びカテプシンsの阻害剤としてのジ−及びトリペプチドニトリル誘導体 |
CA2360740A1 (en) | 1999-03-02 | 2000-09-08 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compounds useful as reversible inhibitors of cathepsin s |
TW200404789A (en) | 1999-03-15 | 2004-04-01 | Axys Pharm Inc | Novel compounds and compositions as protease inhibitors |
US6313117B1 (en) | 1999-07-30 | 2001-11-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Succinate derivative compounds useful as cysteine protease inhibitors |
WO2001019808A1 (en) | 1999-09-16 | 2001-03-22 | Axys Pharmaceuticals, Inc. | Chemical compounds and compositions and their use as cathepsin s inhibitors |
EP1234821A4 (en) | 1999-12-03 | 2002-10-28 | Ono Pharmaceutical Co | 1,3,4-OXADIAZOLINE DERIVATIVES AND MEDICINES THAT CONTAIN THEIR ACTIVE SUBSTANCE |
BRPI0113286B8 (pt) * | 2000-08-14 | 2021-05-25 | Johnson & Johnson | pirazóis substituídos e composição farmacêutica compreendendo os mesmos. |
-
2001
- 2001-08-10 BR BRPI0113286A patent/BRPI0113286B8/pt not_active IP Right Cessation
- 2001-08-10 PL PL360696A patent/PL213103B1/pl unknown
- 2001-08-10 RU RU2003107016/04A patent/RU2317988C2/ru not_active Application Discontinuation
- 2001-08-10 AT AT01965898T patent/ATE320427T1/de active
- 2001-08-10 US US09/927,324 patent/US6953793B2/en not_active Expired - Lifetime
- 2001-08-10 AU AU2001286454A patent/AU2001286454B2/en not_active Expired
- 2001-08-10 NZ NZ524191A patent/NZ524191A/en not_active IP Right Cessation
- 2001-08-10 PT PT01965898T patent/PT1309593E/pt unknown
- 2001-08-10 EP EP01965898A patent/EP1309593B1/en not_active Expired - Lifetime
- 2001-08-10 KR KR1020037002163A patent/KR100837193B1/ko active IP Right Grant
- 2001-08-10 ES ES01965898T patent/ES2261463T3/es not_active Expired - Lifetime
- 2001-08-10 AU AU8645401A patent/AU8645401A/xx active Pending
- 2001-08-10 CZ CZ2003-429A patent/CZ307185B6/cs not_active IP Right Cessation
- 2001-08-10 DE DE60118004T patent/DE60118004T2/de not_active Expired - Lifetime
- 2001-08-10 DK DK01965898T patent/DK1309593T3/da active
- 2001-08-10 CA CA2419552A patent/CA2419552C/en not_active Expired - Lifetime
- 2001-08-10 WO PCT/US2001/025290 patent/WO2002014315A2/en active IP Right Grant
- 2001-08-10 HU HU0303108A patent/HU230538B1/hu not_active IP Right Cessation
- 2001-08-10 JP JP2002519455A patent/JP5049447B2/ja not_active Expired - Lifetime
- 2001-08-10 MX MXPA03001422A patent/MXPA03001422A/es active IP Right Grant
-
2003
- 2003-07-10 HK HK03104996A patent/HK1055422A1/xx not_active IP Right Cessation
-
2005
- 2005-06-30 US US11/174,077 patent/US20050245576A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0113286A (pt) | Pirazóis substituìdos | |
DK1309592T3 (da) | Substituerede pyrazoler | |
CY1106032T1 (el) | Υποκατασταθεισες πυραζολες | |
NO20030845D0 (no) | Utvalgte fusjonerte pyrrolokarbazoler | |
EA200201214A1 (ru) | Замещенные тиоацетамиды | |
IL160440A (en) | Dihydropteridinones, method for producing the same and the use thereof as medicaments | |
ECSP055584A (es) | Proceso para la preparación de fibrinógeno | |
BG66084B1 (bg) | Циклопентаноиндоли, състави,съдържащи такива съединения и използването им | |
NO991732L (no) | Nye heterocyklylmetylsubstituerte pyrazolderivater | |
BRPI0113162B8 (pt) | compostos ariloxialquilaminas nao-imidazólicos e composição farmacêutica compreendendo os referidos compostos | |
CY1108808T1 (el) | Ενωσεις μοτιλιδης | |
MXPA03010766A (es) | Nuevos compuestos y composiciones como inhibicores de las catepsinas. | |
SE0003476D0 (sv) | Compounds | |
TR200503401T1 (tr) | Kuetiapin (Quetiapine) Fumarat'ın yeni polimorfları | |
DK1204659T3 (da) | Serotonerge benzofuraner | |
SE9904128D0 (sv) | Novel compounds | |
MXPA04004090A (es) | Compuestos substituidos de 1h-quinolin-2-ona. | |
BR0214886A (pt) | Fenilalquinos | |
PT1244614E (pt) | Inibidores de triptase | |
CO5150221A1 (es) | Nuevas 3-fenoxi- y 3-fenilalquiloxi-2-fenil-propilaminas sustituidas | |
SE0002045D0 (sv) | New use | |
TR200402685T4 (tr) | Merkezi sinir sistemi üzerine etki eden siklobüta-indol karboksamid türevleri, bunların hazırlanma yöntemleri ve bunları içeren farmasötik bileşimler. | |
DK1366033T3 (da) | Kemiske forbindelser | |
MXPA03003466A (es) | Derivados de piranosido. | |
ATE349427T1 (de) | Tryptaseinhibitoren |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Free format text: JOHNSON & JOHNSON (US) |
|
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Free format text: PARA:INT.CI. C07D 401/14, C07D 413/14, C07D 471/04, C07D 519/00, A61K 31/4162, A61K 31/437, A61K 31/454, A61K 31/4545, A61K 31/495, A61K 31/517, A61K 31/538, A61K 31/5383, A61K 31/549, A61P 11/06, A61P 19/02, A61P 29/00, A61P 37/06, A61P 43/00 Ipc: C07D 401/14 (2006.01), C07D 413/14 (2006.01), C07D |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 16/04/2013, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/08/2001 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 21A ANUIDADE. |
|
B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2682 DE 31-05-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |